BAT for the SLS Control arm patients has failed 5 Trials in the last year / Aza+Ven has failed to increase survival in 3 phase 3 trials and 2 phase 2’s. - while we are seeing unheard of, extended miraculous survival in the SLS Regal P3.
While we are seeing extended near miraculous ALL Pooled Survival in the SLS REGAL Phase 3
- nearly 40% Survival at 3 years - in a transplant ineligible, Post Salvage AML Second Remission (CR2) Population with a expected MOS of just 6-8 months.
BAT / Aza+VEN / Onureg + Venclexta FAILED to Increase OS in 5 TRIALS:
• VERONA Phase 3 $ABBV FAILED high risk MDS/AML Precursor
• VIALE-M Phase 3 $ABBV FAILED - AML FIRST REMISSION (CR1)
• VIALE-T Phase 3 $ABBV FAILED - AML Post Transplant Maintenance
• Opti-AML Phase 2 MDACC Reduced Intensity FAILED
• Paradigm Phase 2 AML Front Line Modified Dosing again FAILED to Increase Survival.
-- Details on each trial https://stocktwits.com/55X_ROI_Q1_2026 - scroll through for DD if you like money. SLS is about to Go Vertical ---
Paradigm P2.
Interesting Look at BAT / Aza+VEN vs Intensive Chemo 7+3
EFS / left Chart AzaVEN a bit better
OS / right Chart Intensive Chemo . . . much better than AzaVEN for OS
and of course Transplant // EFS and OS is the only real treatment option ... Until GPS.
also, does everyone Understand the VDM Stat trial CONFIRMS GPS is 100% for Sure Golden? 18.6% Survival at 3 Years, Net Adjusted MOS of just 8-10 months....
net adjustments: VDM 16.4 months included the time required to obtain a second remission 1-4 months
Patients were transplanted at an exceptionally 50% high rate.
Patients Median age 58 is much lower than REGAL Patients 68 -70 average ... Age is the Number 1 Prognostic factor for Survival - more than any other - a full decade of youth nearly doubles survival. look it up.
if not let me know...
I've been here longer than most, if you like money, Scroll my posts, you will see SLS is the Investment opportunity of a lifetime.
- Imminent Gps P3 Trial data is worth 20x the current $2.3B mcap / $11.50 will be $120 and Climbing the Instant the market sees the data.
- Very similar to what just happened at $MRNA
and for those who may not know and want a hedge, (scroll my posts) the secondary asset SLS009 - the most selective on target and first ever SafeCD Kinase 9 inhibitor - is right now worth 2X - 3X the rigged Mcap.